J Korean Cancer Assoc.
2000 Oct;32(5):943-953.
Potentials of Fractionated Infusions of Low-dose Peripheral Blood Stem Cells
(PBSCs) to Overcome the Hematologic Toxocities after Combination Chemotherapy
- Affiliations
-
- 1Catholic Hematopoietic Stem Cell Transplantation Center, Departments of College of Medicine, The Catholic University of Korea, Seoul, Korea.
- 2Obstetrics and GynecologyCollege of Medicine, The Catholic University of Korea, Seoul, Korea.
- 3Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Abstract
-
PURPOSE: We tried to evaluate the clinical usefullness of fractionated low-dose infusions of peripheral blood stem cells (PBSCs) as a supportive care.
MATERIALS AND METHODS
Four patients were entered onto this study who were diagnosed to have
gastric lymphoma (n=1) and advanced ovarian carcinomas (n=3). To overcome the hematologic
toxicities, G-CSF-mobilized PBSCs were collected early in disease course. Harvested products
were cryopreserved in aliquotes and then infused after each cycle. Planned therapeutic schedules should be performed without changes of dose and interval regardless of hematologic toxicities.
RESULTS
20 cycles of chemotherapies were performed and data of infused cell doses were as
follows: median number of PBSCs infusions, 4.5 (3~5); median MNCs, CFU-GM colony counts
per infusion of low-dose PBSCs, 1.7 108/kg (1.0~2.4), 3.2 104/kg (2.1~11.8). Among 20
cycles, delayed recovery of thrombocytopenia was shown on 10 cycles. Leukopenia (III/IV) and
thrombocytopenia (III/IV) were shown on 8/6 cycles and 8/2 cycles. In spite of myelosuppression, they were successfully treated with planned dose-intensity. Especially incomplete platelet recovery was successfully rescuced by using fractionated infusions of low-dose PBSCs.
CONCLUSION
These data warrant further clinical trials to evaluate the potentials of fractionated low-dose infusions of PBSCs collected early in disease course for overcoming accumulated hematologic toxicities, especially thrombocytopenia complicated by repeated chemotherapies.